{"id":11451,"date":"2025-10-03T20:40:29","date_gmt":"2025-10-03T20:40:29","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-quality-of-life-qol\/"},"modified":"2025-10-04T08:40:16","modified_gmt":"2025-10-04T08:40:16","slug":"hypertermie-kvalitu-zivota-qol","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/sk\/hypertermie-kvalitu-zivota-qol\/","title":{"rendered":"Vplyv hypertermie na kvalitu \u017eivota (QoL): \u00da\u013eava od bolesti, zn\u00ed\u017eenie \u00fanavy a adjuvantn\u00e9 imunologick\u00e9 pr\u00ednosy"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Vplyv hypertermie na kvalitu \u017eivota (QoL): \u00da\u013eava od bolesti, zn\u00ed\u017eenie \u00fanavy a adjuvantn\u00e9 imunologick\u00e9 pr\u00ednosy\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrum Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hypertermia, Onkol\u00f3gia, klinick\u00e1 \u0161t\u00fadia f\u00e1zy III, QoL, boles\u0165, E-E-A-T\"\n      \/*... Sch\u00e9ma FAQPage by sa pridala osobitne pre sekciu \u010casto kladen\u00e9 ot\u00e1zky *\/\n    }\n<\/script><\/p>\n<article>\n<header>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autorita a Odbornos\u0165 (EEAT): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autor: <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sk\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , MD, a <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sk\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Vplyv hypertermie na kvalitu \u017eivota (QoL): \u00da\u013eava od bolesti, zn\u00ed\u017eenie \u00fanavy a adjuvantn\u00e9 imunologick\u00e9 pr\u00ednosy<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V modernej onkol\u00f3gii sa mana\u017ement rakoviny zameriava na optim\u00e1lnu rovnov\u00e1hu medzi<a href=\"https:\/\/andromedichyperthermia.com\/sk\/hypertermia-prezitie-pacientov\/\"> Pre\u017eit\u00edm (OS\/DFS)<\/a> a <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kvalitou \u017divota (QoL).<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Hypertermia (HT) predstavuje jedine\u010dn\u00fa adjuvantn\u00fa modalitu, ktor\u00e1 v rozsiahlych klinick\u00fdch \u0161t\u00fadi\u00e1ch ( <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sk\/hypertermie-studii-fazy-iii\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RCT f\u00e1zy III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ) preuk\u00e1zala zlep\u0161enie QoL na viacer\u00fdch \u00farovniach: kontrola sympt\u00f3mov, celkov\u00fd funk\u010dn\u00fd stav a vynikaj\u00faci bezpe\u010dnostn\u00fd profil.<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Hlavn\u00fd Paliat\u00edvny Pr\u00ednos: Kontrola Bolesti (d\u00f4kazy \u00farovne A1 z klinick\u00fdch \u0161t\u00fadi\u00ed F\u00e1zy III)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Metastatick\u00e1 boles\u0165 kost\u00ed zni\u017euje QoL. Lokoregion\u00e1lna RF hypertermia, kombinovan\u00e1 s R\u00e1dioterapiou (RT), poskytuje vynikaj\u00facu paliat\u00edvnu kontrolu, pod\u013ea <\/span><\/span><a href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0161t\u00fadie F\u00e1zy III publikovanej Chi MS a kol<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. (2017)[1]:<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL Ukazovate\u013e\/Zlep\u0161enie Bolesti<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoterapia<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hypertermia (HT)<\/span><\/span><\/th>\n<th>Vplyv na QoL<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Miera Kompletnej Odpovede (CR) po 3 Mesiacoch<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (nulov\u00e9 sk\u00f3re bolesti)<\/span><\/span><\/td>\n<td>7,1 %<\/td>\n<td>37,9 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">533 % n\u00e1rast \u0161anc\u00ed na \u00fapln\u00e9 odstr\u00e1nenie bolesti.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Trvanie \u00da\u013eavy od Bolesti<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medi\u00e1n: 55 dn\u00ed\/7,9 t\u00fd\u017ed\u0148a<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medi\u00e1n: Nedosiahnut\u00e9 v 24. t\u00fd\u017edni<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Trvanie \u00fa\u013eavy sa strojn\u00e1sobuje, zni\u017euje sa z\u00e1vislos\u0165 na analgetik\u00e1ch.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V roku <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0306456524000226?via%3Dihub\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2024 publikovali Sahinbas a kolegovia \u0161t\u00fadiu F\u00e1zy III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> pre boles\u0165 kostn\u00fdch metast\u00e1z, preva\u017ene z rakoviny prsn\u00edka a prostaty, s pou\u017eit\u00edm WBHT wIRA hypertermie navy\u0161e k RT.[2]<\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Na z\u00e1klade tejto \u0161t\u00fadie vykazovala skupina lie\u010den\u00e1 iba r\u00e1dioterapiou (RT) najintenz\u00edvnej\u0161iu boles\u0165. \u0160t\u00fadia bola dokon\u010den\u00e1 po zaraden\u00ed celkovo 61 pacientov, 5 rokov po prvom zaraden\u00ed (apr\u00edl 2016 \u2013 febru\u00e1r 2021). Napokon miera CR v skupine RT + WBH uk\u00e1zala najv\u00fdznamnej\u0161\u00ed rozdiel oproti samotnej RT, a to 47,4 % vs. 5,3 %, v priebehu 2 mesiacov po lie\u010dbe (hodnota P &lt; 0,05). Doba do \u00faplnej \u00fa\u013eavy od bolesti bola 10 dn\u00ed pre RT + WBH, zatia\u013e \u010do v skupine RT v monoterapii nebolo dosiahnut\u00e9 kone\u010dn\u00e9 krit\u00e9rium. Progresia bolesti alebo stabilita ochorenia boli pozorovan\u00e9 u polovice pacientov v skupine RT do 4 t\u00fd\u017ed\u0148ov po lie\u010dbe. Av\u0161ak, toto sk\u00f3re bolo takmer nulov\u00e9 u pacientov RT + WBHT po\u010das dvoch mesiacov po lie\u010dbe.<\/span><\/span><\/span><\/p>\n<p><strong class=\"sub-title\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Z\u00e1very:\u00a0<\/span><\/span><\/span><\/strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> WBH plus RT preuk\u00e1zali v\u00fdznamn\u00e9 zv\u00fd\u0161enie \u00fa\u013eavy od bolesti a krat\u0161iu dobu odpovede v porovnan\u00ed so samotnou RT u pacientov s metastatick\u00fdmi kostn\u00fdmi l\u00e9ziami.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL Ukazovate\u013e\/Zlep\u0161enie Bolesti<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoterapia<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hypertermia (WBHT wIRA)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Vplyv na QoL<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Miera Kompletnej Odpovede (CR) po 2 Mesiacoch<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (nulov\u00e9 sk\u00f3re bolesti)<\/span><\/span><\/td>\n<td>5,3 %<\/td>\n<td>47,4 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">894 % n\u00e1rast<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * \u0161anc\u00ed na \u00fapln\u00e9 odstr\u00e1nenie bolesti.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Doba do \u00faplnej \u00fa\u013eavy od bolesti<\/span><\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">nebola dosiahnut\u00e1<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">10 dn\u00ed<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\">V\u00fdznamn\u00fd a R\u00fdchly Pr\u00ednos<\/span><\/strong><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Trvanie \u00da\u013eavy od Bolesti\u00a0<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medi\u00e1n: 28 dn\u00ed\/4 t\u00fd\u017edne u polovice pacientov<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medi\u00e1n: Nedosiahnut\u00e9 v 24. t\u00fd\u017edni<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Trvanie \u00fa\u013eavy * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">sa zvy\u0161uje \u0161es\u0165kr\u00e1t<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> *, zni\u017euje sa z\u00e1vislos\u0165 na analgetik\u00e1ch.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Zlep\u0161enie Funk\u010dn\u00e9ho Stavu a Zn\u00ed\u017eenie \u00danavy<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pr\u00ednos HT na QoL je priamo merate\u013en\u00fd pomocou \u0161tandardizovan\u00fdch dotazn\u00edkov (EORTC QLQ-C30), preukazuj\u00fac zlep\u0161enie celkov\u00e9ho stavu (Fyzick\u00e1 Funkcia, \u00danava a \u00dazkos\u0165):<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V\u00fdznamne Zlep\u0161en\u00e1 QoL (modulovan\u00e1 RF hypertermia mHT):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Randomizovan\u00e1 klinick\u00e1 \u0161t\u00fadia Modulovanej RF Hypertermie (mEHT) pri karcin\u00f3me kr\u010dka maternice (LACC) zaznamenala v\u00fdznamn\u00e9 zlep\u0161enie dlhodob\u00fdch sk\u00f3re QoL, pri\u010dom pacienti hl\u00e1sili lep\u0161ie v\u00fdsledky na \u0161k\u00e1lach Fyzickej a Emocion\u00e1lnej Funkcie.[3]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kontrola \u00danavy a Imunomodul\u00e1cia:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Celotelov\u00e1 Hypertermia (WBHT) a HT v\u0161eobecne pozit\u00edvne ovplyv\u0148uj\u00fa chronick\u00fa \u00fanavu (CRF) modul\u00e1ciou proz\u00e1palov\u00fdch cytok\u00ednov (IL-6, TNF-alfa). HT tie\u017e pom\u00e1ha udr\u017eiava\u0165 a zlep\u0161ova\u0165 sk\u00f3re na \u0161k\u00e1lach Fyzickej a Emocion\u00e1lnej Funkcie dlhodobo.[4]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">R\u00fdchle Emocion\u00e1lne Zotavenie (HIPEC):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Po rozsiahlych chirurgick\u00fdch z\u00e1krokoch, ktor\u00e9 zah\u0155\u0148aj\u00fa HT (HIPEC), m\u00e1 emo\u010dn\u00e1 QoL tendenciu sa r\u00fdchlo zlep\u0161ova\u0165, za\u010d\u00ednaj\u00fac u\u017e *3 mesiace po oper\u00e1cii, \u010dasto prekra\u010duj\u00fac z\u00e1kladn\u00e9 \u00farovne.[5]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Konsolid\u00e1cia Dlhodob\u00fdch QoL Pr\u00ednosov<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u00dadaje z re\u00e1lneho sveta a klinick\u00e9 \u0161t\u00fadie pri pokro\u010dil\u00fdch karcin\u00f3moch potvrdzuj\u00fa \u00falohu hypertermie pri stabiliz\u00e1cii a zlep\u0161ovan\u00ed dlhodobej QoL:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kurativn\u00fd Vplyv po 12 Mesiacoch:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Rozsiahla anal\u00fdza pacientov lie\u010den\u00fdch s kurat\u00edvnym z\u00e1merom (RCT + HT) preuk\u00e1zala v\u00fdznamn\u00e9 zlep\u0161enie, udr\u017eiavan\u00e9 po *dobu 12 mesiacov, v sk\u00f3re na pod\u0161k\u00e1lach QoL hodnotiacich **Emocion\u00e1lnu Funkciu, Soci\u00e1lnu Funkciu* a *Nespavos\u0165 (SL)*, v porovnan\u00ed s onkologickou referen\u010dnou popul\u00e1ciou EORTC.[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Paliat\u00edvne Pr\u00ednosy:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> V paliat\u00edvnom kontexte viedlo pridanie HT ku \u0161tandardnej lie\u010dbe ku klinicky relevantn\u00e9mu zlep\u0161eniu *Bolesti (PA)* a zn\u00ed\u017eeniu *Finan\u010dn\u00fdch \u0164a\u017ekost\u00ed (FI)* *3 mesiace po lie\u010dbe*, \u010do prispelo k lep\u0161iemu celkov\u00e9mu stavu pacienta.[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Zlep\u0161en\u00e1 QoL pri Pokro\u010dilom Ochoren\u00ed (Kolorekt\u00e1lny Karcin\u00f3m):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> V \u0161t\u00fadii hodnotiacej Vysokofrekven\u010dn\u00fa Hypertermiu asistovan\u00fa chemoterapiou u pacientov so stredn\u00fdm a pokro\u010dil\u00fdm \u0161t\u00e1diom kolorekt\u00e1lneho karcin\u00f3mu, skupina, ktor\u00e1 dostala kombin\u00e1ciu, vyk\u00e1zala v\u00fdznamne vy\u0161\u0161ie (zlep\u0161en\u00e9) sk\u00f3re QoL po 4 cykloch lie\u010dby, \u010do dokazuje, \u017ee HT \u00fa\u010dinne zlep\u0161uje QoL, okrem terapeutick\u00fdch \u00fa\u010dinkov, pri zachovan\u00ed lep\u0161ej bezpe\u010dnosti.[11]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Adjuvantn\u00e9 Biologick\u00e9 Pr\u00ednosy a Vy\u0161\u0161\u00ed Terapeutick\u00fd Index<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT maximalizuje letalitu lie\u010dby bez v\u00fdznamn\u00e9ho zv\u00fd\u0161enia rizika z\u00e1va\u017enej toxicity (Stupe\u0148 3-4), \u010d\u00edm udr\u017eiava vysok\u00fd Terapeutick\u00fd Index:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Validovan\u00e1 Bezpe\u010dnos\u0165 (klinick\u00e9 \u0161t\u00fadie F\u00e1zy III):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Meta-anal\u00fdzy pri karcin\u00f3me kr\u010dka maternice preukazuj\u00fa \u017eiadny v\u00fdznamn\u00fd rozdiel v ak\u00fatnej alebo neskorej toxicite (RR Toxicita 1.01).[6] Bezpe\u010dnostn\u00fd profil je udr\u017eiavan\u00fd pri Rakovine Kone\u010dn\u00edka[7] a v \u0161t\u00fadi\u00e1ch Rakoviny Pankreasu[8].<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ochrana Org\u00e1nov:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Pri Rakovine Kone\u010dn\u00edka zvy\u0161uje pridanie HT k neoadjuvantnej chemoradioterapii 5-ro\u010dn\u00e9 Pre\u017eitie Bez Kolost\u00f3mie (CFS) zo 69,0 % na 87,7 %, \u010do je ve\u013ek\u00fd funk\u010dn\u00fd pr\u00ednos pre QoL.[7]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Abskop\u00e1lny Efekt (Vakc\u00edne Podobn\u00fd):<\/strong> HT sp\u00fa\u0161\u0165a imunog\u00e9nnu bunkov\u00fa smr\u0165, uvo\u013e\u0148uje Prote\u00edny Teplotn\u00e9ho \u0160oku (HSPs), ktor\u00e9 aktivuj\u00fa cytotoxick\u00e9 CD8+ T bunky. Toto syst\u00e9mov\u00e9 imunologick\u00e9 primovanie prispieva ku kontrole zvy\u0161kovej choroby a je z\u00e1sadn\u00fdm adjuvantn\u00fdm pr\u00ednosom.[9]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Z\u00e1ver: Terapia Zameran\u00e1 na Pacienta<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Integr\u00e1cia Hypertermie do onkologick\u00e9ho protokolu predstavuje pokro\u010dil\u00fa, na d\u00f4kazoch zalo\u017een\u00fa strat\u00e9giu, ktor\u00e1 nielen zlep\u0161uje Pre\u017eitie, ale tie\u017e poskytuje robustn\u00fa kontrolu sympt\u00f3mov a udr\u017euje Kvalitu \u017divota. \u00da\u013eava od bolesti, kontrola \u00fanavy a vynikaj\u00faci bezpe\u010dnostn\u00fd profil robia z HT nevyhnutn\u00fd prvok holistickej starostlivosti o onkologick\u00e9ho pacienta.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Poz\u00fdvame v\u00e1s na konzult\u00e1ciu s na\u0161imi odborn\u00edkmi, aby ste integrovali Hypertermiu do v\u00e1\u0161ho protokolu s cie\u013eom maximalizova\u0165 tak \u00fa\u010dinnos\u0165, ako aj Kvalitu \u017divota.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EEAT Z\u00e1ruka:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Tento obsah je zalo\u017een\u00fd na publikovan\u00fdch \u00fadajoch z randomizovan\u00fdch a prospekt\u00edvnych klinick\u00fdch \u0161t\u00fadi\u00ed F\u00e1zy III, ktor\u00e9 vyu\u017e\u00edvaj\u00fa \u0161tandardizovan\u00e9 n\u00e1stroje na meranie Kvality \u017divota (EORTC QLQ-C30). \u00dapln\u00e9 referencie s\u00fa integrovan\u00e9 s priamymi odkazmi na zdrojov\u00e9 publik\u00e1cie.<\/span><\/span><\/small><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Referencie:<\/span><\/span><\/p>\n<ol>\n<li>Chi MS, Yang KL, Chang YC, Ko HL, Lin YH, Huang SC, Huang YY, Liao KW, Kondo M, Chi KH. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78-87. doi: 10.1016\/j.ijrobp.2017.09.030. Epub 2017 Sep 21. PMID: 29066122.<\/li>\n<li>Faghihi Moghaddam F, Bakhshandeh M, Mofid B, Sahinbas H, Faeghi F, Mirzaei H, Rakhsha A, Yousefi Kashi AS, Sadeghi R, Mahdavi A. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. J Therm Biol. 2024 Feb;120:103804. doi: 10.1016\/j.jtherbio.2024.103804. Epub 2024 Feb 23. PMID: 38460451.<\/li>\n<li>Minnaar CA, Maposa I, Kotzen JA, Baeyens A. Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients. Cancers (Basel). 2022 Jan 27;14(3):656. doi: 10.3390\/cancers14030656. PMID: 35158924; PMCID: PMC8833695.<\/li>\n<li>Ostberg, K., et al. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol. 2008 Jul;27(7):849-56. doi: 10.1007\/s10067-007-0785-5. Epub 2007 Oct 20. PMID: 17948286.<\/li>\n<li>Morgan RB, Tun S, Eng OS. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a narrative review. Curr Probl Surg. 2020 Jan;57(1):100693. doi: 10.1016\/j.cpsurg.2019.100693. Epub 2020 Jan 29. PMID: 32063294.<\/li>\n<li>Chia BSH, Ho SZ, Tan HQ, Chua MLK, Tuan JKL. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel). 2023 Jan 5;15(2):346. doi: 10.3390\/cancers15020346. PMID: 36672300; PMCID: PMC9856725.<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). <a href=\"https:\/\/doi.org\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/a><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li>Baronzio, G. F., et al. Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Front Oncol. 2020 Nov 24;10:591932. doi: 10.3389\/fonc.2020.591932. PMID: 33324545; PMCID: PMC7721869.<\/li>\n<li>Linnenbank, W. I., et al. Real-World Analysis of Quality of Life and Toxicity in Cancer Patients Treated with Hyperthermia Combined with Radiochemotherapy. Cancers (Basel). 2023 Feb 1;15(3):880. doi: 10.3390\/cancers15030880. PMID: 36765790; PMCID: PMC9954584.<\/li>\n<li>Liu, Z. Clinical effects of high frequency hyperthermia-assisted irinotecan chemotherapy on patients with middle and advanced colorectal cancer and its safety assessment. Oncol Lett. 2019 Jan;17(1):215-220. doi: 10.3892\/ol.2018.9574. Epub 2018 Oct 12. PMID: 30655758; PMCID: PMC6313175.<\/li>\n<\/ol>\n<\/footer>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autorita a Odbornos\u0165 (EEAT): Autor: Dr. Veronica Iatan , MD, a Cristian Gologan M.Sc , Andromedichyperthermia Vplyv hypertermie na kvalitu \u017eivota (QoL): \u00da\u013eava od bolesti, zn\u00ed\u017eenie \u00fanavy a adjuvantn\u00e9 imunologick\u00e9 pr\u00ednosy V modernej onkol\u00f3gii sa mana\u017ement rakoviny zameriava na optim\u00e1lnu rovnov\u00e1hu medzi Pre\u017eit\u00edm (OS\/DFS) a Kvalitou \u017divota (QoL). Hypertermia (HT) predstavuje jedine\u010dn\u00fa adjuvantn\u00fa modalitu, ktor\u00e1&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[179,999,30],"tags":[1061,1000,1001,1002,758,1060,765,1005,1006],"class_list":["post-11451","post","type-post","status-publish","format-standard","hentry","category-news-sk","category-studii-clinice-sk","category-uncategorized-sk","tag-bolest-sk","tag-calitatea-vietii-sk","tag-durere-sk","tag-hipertermie-oncologica-sk","tag-hypertermia","tag-klinicka-studia-fazy-iii","tag-onkologia-sk","tag-qol-sk","tag-studii-faza-iii-sk"],"gutentor_comment":1,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/posts\/11451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/comments?post=11451"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/posts\/11451\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/media?parent=11451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/categories?post=11451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/tags?post=11451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}